Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors

ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38) with the PARP inhibitor Rubraca® (rucaparib) at the National Cancer Institute   SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the first patient was treated with its PLX038 in a Phase 1B clinical trial for small-cell lung cancer at the...

Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...

ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...